Lipoprotein(a) is associated with necrotic core progression of non-culprit coronary lesions in statin-treated patients with angina pectoris

Lipids in Health and Disease

Volumn 13, Issue 1, 2014, Pages

  Nozue, Tsuyoshi ^a   Yamamoto, Shingo ^b   Tohyama, Shinichi ^c   Fukui, Kazuki ^d   Umezawa, Shigeo ^e   Onishi, Yuko ^e   Kunishima, Tomoyuki ^f   Sato, Akira ^g   Nozato, Toshihiro ^h   Miyake, Shogo ⁱ   Takeyama, Youichi ^j   Morino, Yoshihiro ^k   Yamauchi, Takao ^l   Muramatsu, Toshiya ^m   Hibi, Kiyoshi ⁿ   Terashima, Mitsuyasu ^o   Michishita, Ichiro ^a  

^a YOKOHAMA SAKAE KYOSAI HOSPITAL   (Japan)

^b Tsurumi Nishiguchi Hospital   (Japan)

^c Yokohama Seamen's Insurance Hospital   (Japan)

^d Kanagawa Prefectural Cardiovascular and Respiratory Diseases Center Hospital   (Japan)

^e Hiratsuka Kyosai Hospital   (Japan)

^f TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g YOKOSUKA KYOSAI HOSPITAL   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION   (Japan)

ⁱ Ebina General Hospital   (Japan)

^j SHOWA UNIVERSITY   (Japan)

^k TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^m SAISEIKAI YOKOHAMASHI TOBU HOSPITAL   (Japan)

ⁿ YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^o Cardiovascular Imaging Center   (Japan)

more..

Author keywords

Lipoprotein (a); Necrotic core; Statin; Virtual histology intravascular ultrasound

Indexed keywords

ANTILIPEMIC AGENT; LIPOPROTEIN A; PITAVASTATIN; PRAVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DENSE CALCIUM PLAQUE VOLUME; DISEASE COURSE; FEMALE; FIBRO FATTY PLAQUE VOLUME; FOLLOW UP; HUMAN; INTRAVASCULAR ULTRASOUND; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NECROTIC CORE PROGRESSION; OPEN STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STABLE ANGINA PECTORIS; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; ATHEROSCLEROTIC PLAQUE; BLOOD; CORONARY ARTERY DISEASE; MIDDLE AGED; PATHOLOGY;

AGED; ANGINA PECTORIS; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC;

EID: 84898895797     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-13-59     Document Type: Article

References (44)

1. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, Treating to New Targets (TNT) Investigators, N Engl J Med 2005 352 1425 1435 10.1056/NEJMoa050461 15755765 (Pubitemid 40471450)
2. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. Nicholls SJ, Hsu A, Wolski K, Hu B, Bayturan O, Lavoie A, Uno K, Tuzcu EM, Nissen SE, J Am Coll Cardiol 2010 55 2399 2407 10.1016/j.jacc.2010.02.026 20488313
3. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, Shiomi M, Schoen FJ, Libby P, Circulation 2001 103 276 283 10.1161/01.CIR.103.2. 276 11208689 (Pubitemid 32095415)
4. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Nair A, Kuban BD, Tuzcu EM, Schoenhagen P, Nissen SE, Vince DG, Circulation 2002 106 2200 2206 10.1161/01.CIR.0000035654.18341.5E 12390948 (Pubitemid 35222213)
5. Current concepts of the pathogenesis of the acute coronary syndromes. Libby P, Circulation 2001 104 365 372 10.1161/01.CIR.104.3.365 11457759 (Pubitemid 32666962)
6. Usefulness of virtual histology intravascular ultrasound to predict distal embolization for ST-segment elevation myocardial infarction. Kawaguchi R, Oshima S, Jingu M, Tsurugaya H, Toyama T, Hoshizaki H, Taniguchi K, J Am Coll Cardiol 2007 50 1641 1646 10.1016/j.jacc.2007.06.051 17950144 (Pubitemid 47562679)
7. Statin treatment for coronary artery plaque composition based on intravascular ultrasound radiofrequency data analysis. Nozue T, Yamamoto S, Tohyama S, Umezawa S, Kunishima T, Sato A, Miyake S, Takeyama Y, Morino Y, Yamauchi T, Muramatsu T, Hibi K, Sozu T, Terashima M, Michishita I, Am Heart J 2012 163 191 199 10.1016/j.ahj.2011.11.004 22305836
8. Effect of fluvastatin on progression of coronary atherosclerotic plaque evaluated by virtual histology intravascular ultrasound. Nasu K, Tsuchikane E, Katoh O, Tanaka N, Kimura M, Ehara M, Kinoshita Y, Matsubara T, Matsuo H, Asakura K, Asakura Y, Terashima M, Takayama T, Honye J, Hirayama A, Saito S, Suzuki T, JACC Cardiovasc Interv 2009 2 689 696 19628194
9. Effect of intensive atorvastatin therapy on coronary atherosclerosis progression, composition, arterial remodeling, and microvascular function. Eshtehardi P, McDaniel MC, Dhawan SS, Binongo JN, Krishnan SK, Golub L, Corban MT, Raggi P, Quyyumi AA, Samady H, J Invasive Cardiol 2012 24 522 529 23043036
10. Effects of statin treatments on coronary plaques assessed by volumetric virtual histology intravascular ultrasound analysis. Hong MK, Park DW, Lee CW, Lee SW, Kim YH, Kang DH, Song JK, Kim JJ, Park SW, Park SJ, JACC Cardiovasc Interv 2009 2 679 688 10.1016/j.jcin.2009.03.015 19628193
11. American college of cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of Intravascular Ultrasound Studies (IVUS). a report of the American college of cardiology task force on clinical expert consensus documents. Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, Pinto FJ, Rosenfield K, Siegel RJ, Tuzcu EM, Yock PG, J Am Coll Cardiol 2001 37 1478 1492 10.1016/S0735-1097(01)01175-5 11300468 (Pubitemid 32295620)
12. Simple and practical sandwich-type enzyme immunoassay for human oxidatively modified low density lipoprotein using antioxidized phosphatidylcholine monoclonal antibody and antihuman apolipoprotein-B antibody. Kohno H, Sueshige N, Oguri K, Izumidate H, Masunari T, Kawamura M, Itabe H, Takano T, Hasegawa A, Nagai R, Clin Biochem 2000 33 243 253 10.1016/S0009- 9120(00)00065-5 10936581 (Pubitemid 30670174)
13. Relationship between apo[a] isoforms and Lp[a] density in subjects with different apo[a] phenotype: a study before and after a fatty meal. Pfaffinger D, Schuelke J, Kim C, Fless GM, Scanu AM, J Lipid Res 1991 32 679 683 1830325
14. Evaluation of a new automated latex agglutination assay for lipoprotein(a): comparison with a manual ELISA. Gaw A, Gourlay CW, Brown EA, Bell MA, Clin Chim Acta 1997 261 175 183 10.1016/S0009-8981(97)06524-8 9201437 (Pubitemid 27214575)
15. Development of a homogeneous assay for measurement of small dense LDL cholesterol. Ito Y, Fujimura M, Ohta M, Hirano T, Clin Chem 2011 57 57 65 10.1373/clinchem.2010.149559 21051530
16. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. Ariyo AA, Thach C, Tracy R, Cardiovascular Health Study Investigators, N Engl J Med 2003 349 2108 2115 10.1056/NEJMoa001066 14645638 (Pubitemid 37464535)
17. Lipoprotein(a) and coronary heart disease Meta-analysis of prospective studies. Danesh J, Collins R, Peto R, Circulation 2000 102 1082 1085 10.1161/01.CIR.102.10.1082 10973834
18. Lipoprotein(a): new insights into mechanisms of atherogenesis and thrombosis. Deb A, Caplice NM, Clin Cardiol 2004 27 258 264 10.1002/clc. 4960270503 15188938 (Pubitemid 38703073)
19. Mechanisms of lipoprotein(a) pathogenicity: prothrombotic, proatherosclerotic, or both? Spence JD, Koschinsky M, Arterioscler Thromb Vasc Biol 2012 32 1550 1551 10.1161/ATVBAHA.112.251306 22699275
20. Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. Helgadottir A, Gretarsdottir S, Thorleifsson G, Holm H, Patel RS, Gudnason T, Jones GT, van Rij AM, Eapen DJ, Baas AF, Tregouet DA, Morange PE, Emmerich J, Lindblad B, Gottsäter A, Kiemeny LA, Lindholt JS, Sakalihasan N, Ferrell RE, Carey DJ, Elmore JR, Tsao PS, Grarup N, Jørgensen T, Witte DR, Hansen T, Pedersen O, Pola R, Gaetani E, Magnadottir HB, et al. J Am Coll Cardiol 2012 60 722 729 10.1016/j.jacc.2012.01. 078 22898070
21. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a). Terres W, Tatsis E, Pfalzer B, Beil FU, Beisiegel U, Hamm CW, Circulation 1995 91 948 950 10.1161/01.CIR.91.4.948 7850979
22. Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy. Nicholls SJ, Tang WH, Scoffone H, Brennan DM, Hartiala J, Allayee H, Hazen SL, J Lipid Res 2010 51 3055 3061 10.1194/jlr.M008961 20601648
23. Relation between lipoprotein(a) and fibrinogen and serial intravascular ultrasound plaque progression in left main coronary arteries. Hartmann M, von Birgelen C, Mintz GS, Stoel MG, Eggebrecht H, Wieneke H, Fahy M, Neumann T, van der Palen J, Louwerenburg HW, Verhorst PM, Erbel R, J Am Coll Cardiol 2006 48 446 452 10.1016/j.jacc.2006.03.047 16875967 (Pubitemid 44093948)
24. Lipoprotein(a) as a cardiovascular risk factor: current status. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A, European Atherosclerosis Society Consensus Panel, Eur Heart J 2010 31 2844 2853 10.1093/eurheartj/ehq386 20965889
25. Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease. Nestel PJ, Barnes EH, Tonkin AM, Simes J, Fournier M, White HD, Colquhoun DM, Blankenberg S, Sullivan DR, Arterioscler Thromb Vasc Biol 2013 33 2902 2908 10.1161/ATVBAHA.113.302479 24092750
26. Prognostic significance of elevated lipoprotein(a) in coronary artery revascularization patients. Kwon SW, Lee BK, Hong BK, Kim JY, Choi EY, Sung JM, Rhee JH, Park YM, Ma DW, Chung H, Mun HS, Lee SJ, Park JK, Min PK, Yoon YW, Rim SJ, Kwon HM, Int J Cariol 2013 167 1990 1994 10.1016/j.ijcard.2012.05.007
27. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. Tsimikas S, Hall JL, J Am Coll Cardiol 2012 60 716 721 10.1016/j.jacc.2012.04.038 22898069
28. Increased degradation of lipoprotein(a) in atherosclerotic compared with nonlesioned aortic intima-inner media of rabbits: in vivo evidence that lipoprotein(a) may contribute to foam cell formation. Nielsen LB, Juul K, Nordestgaard BG, Arterioscler Thromb Vasc Biol 1998 18 641 649 10.1161/01.ATV.18.4.641 9555871 (Pubitemid 28177906)
29. Lipoprotein (a) and coronary heart disease. Maher VM, Brown BG, Curr Opin Lipidol 1995 6 229 235 10.1097/00041433-199508000-00007 7670752
30. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F, Wiedermann CJ, Oberthaler S, Xu Q, Witztum JL, Tsimikas S, Arterioscler Thromb Vasc Biol 2007 27 1788 1795 10.1161/ATVBAHA.107. 145805 17541022 (Pubitemid 47207175)
31. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, Berger PB, N Engl J Med 2005 353 46 57 10.1056/NEJMoa043175 16000355 (Pubitemid 41007806)
32. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Seimon TA, Nadolski MJ, Liao X, Magallon J, Nguyen M, Feric NT, Koschinsky ML, Harkewicz R, Witztum JL, Tsimikas S, Golenbock D, Moore KJ, Tabas I, Cell Metab 2010 12 467 482 10.1016/j.cmet.2010.09.010 21035758
33. Automated coronary plaque characterisation with intravascular ultrasound backscatter: ex vivo validation. Nair A, Margolis MP, Kuban BD, Vince DG, EuroIntervention 2007 3 113 120 19737694
34. Comparison of change in coronary atherosclerosis in patients with stable versus unstable angina pectoris receiving statin therapy (from the Treatment With Statin on Atheroma Regression Evaluated by Intravascular Ultrasound With Virtual Histology [TRUTH] study). Nozue T, Yamamoto S, Tohyama S, Fukui K, Umezawa S, Onishi Y, Kunishima T, Sato A, Nozato T, Miyake S, Takeyama Y, Morino Y, Yamauchi T, Muramatsu T, Hibi K, Terashima M, Michishita I, TRUTH Investigators, Am J Cardiol 2013 111 923 929 10.1016/j.amjcard.2012.12.008 23337838
35. A prospective natural-history study of coronary atherosclerosis. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, Mehran R, McPherson J, Farhat N, Marso SP, Parise H, Templin B, White R, Zhang Z, Serruys PW, PROSPECT Investigators, N Engl J Med 2011 364 226 235 10.1056/NEJMoa1002358 21247313
36. Pathology of the vulnerable plaque. Virmani R, Burke AP, Farb A, Kolodgie FD, J Am Coll Cardiol 2006 47 13 C18 10.1016/j.jacc.2005.10.065 16631505
37. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL, Circulation 1989 80 1313 1319 10.1161/01.CIR.80.5.1313 2530005 (Pubitemid 19282521)
38. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ, JAMA 1995 274 1771 1774 10.1001/jama.1995.03530220037029 7500507
39. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). McKenney JM, Jones PH, Bays HE, Knopp RH, Kashyap ML, Ruoff GE, McGovern ME, Atherosclerosis 2007 192 432 437 10.1016/j.atherosclerosis.2006.11.037 17239888 (Pubitemid 46726341)
40. Effect of HELP-LDL-apheresis on serum concentrations of human lipoprotein(a): kinetic analysis of the post-treatment return to baseline levels. Armstrong VW, Schleef J, Thiery J, Muche R, Schuff-Werner P, Eisenhauer T, Seidel D, Eur J Clin Invest 1989 19 235 240 10.1111/j.1365-2362.1989.tb00223. x 2509208 (Pubitemid 19184184)
41. Extended-release niacin or ezetimibe and carotid intima-media thickness. Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M, N Engl J Med 2009 361 2113 2122 10.1056/NEJMoa0907569 19915217
42. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W, AIM-HIGH Investigators, N Engl J Med 2011 365 2255 2267 22085343
43. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. Tsimikas S, Bergmark C, Beyer RW, Patel R, Pattison J, Miller E, Juliano J, Witztum JL, J Am Coll Cardiol 2003 41 360 370 12575961 (Pubitemid 36164488)
44. The immediate effect of streptokinase on serum lipoprotein(a) concentration and the effect of myocardial infarction on serum lipoprotein(a), apolipoproteins A1 and B, lipids and C-reactive protein. MBewu AD, Durrington PN, Bulleid S, Mackness MI, Atherosclerosis 1993 103 65 71 10.1016/0021-9150(93) 90040-2 8280186 (Pubitemid 23313140)